Corticosteroid Treatment in Active Crohn's Disease

[en] Despite recent improvements in the management of Crohn's disease, steroids are still the most efficacious treatment in flare ups of the disease. However they have significant side effects and are only effective in the short term. There is no consensus regarding initial dose or duration of corticotherapy. With 1 mg/Kg a day of oral prednisolone given for 3 to 7 weeks, 92% of the patients achieve clinical remission. Topical acting oral corticosteroids such as budesonide seem to represent an important therapeutic advance due to their better tolerance. The promising results of budesonide in mild and moderate flare ups need to be confirmed and its indication in severe disease beside high dose prednisolone has to be clarified.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Belaiche, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Language :

English

Title :

Corticosteroid Treatment in Active Crohn's Disease

Publication date :

1998

Journal title :

Acta Gastro-Enterologica Belgica

ISSN :

0001-5644

eISSN :

1784-3227

Publisher :

Acta Medica Belgica, Bruxelles, Belgium

Volume :

Issue :

2, Apr-Jun

Pages :

153-7

Available on ORBi :

since 26 November 2009

Statistics

Number of views

40 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

MEYERS S , SACHAR D B Medical therapy of Crohn's disease In : J B. KIRSNER, R G SHORTED (eds), Inflammatory bowel disease (fourth edition). Williams & Wilkins, Baltimore, Philadelphia, 1995, p. 695-714.
SUMMERS R.W., SWITZ D.M., SESSIONS Jr J T. et al. National Cooperative Crohn's Disease Study. results of drug treatment. Gastroenterology, 1979, 77 847-869
MALCHOW H., EWE K , BRANDES J W et al European Cooperative Crohn's Disease Study . results of drug treatment Gastroenterology, 1984, 86 : 249-266.
MUNKHOLM P., LANGHOLZ E, DAVIDSEN M., BINDER V Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut, 1994, 35 : 360-362.
MODIGLIANI R., MARY J Y , SIMON J.F. et al. Clinical, biological and endoscopic picture of attacks of Crohn's disease. evolution on prednisone Gastroenterology, 1990, 98 . 811-818.
BRIGNOLA C., DE SIMONE G., LANNONE I et al Influence of steroid treatment duration in patients with active Crohn's disease Agents actions Special conference issue 1992 C90-C92.
LANDI B, N'GUYEN ANH T , CORTOT A. et al Endoscopic monitoring of Crohn's disease treatment : a prospective randomized clinical trial. Gastroenterology, 1992, 102 1647-1653.
BRIGNOLA C., CAMPIERI M., BAZOCCHI G et al A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology, 1986, 91 : 1490-1494.
BRIGNOLA C., IANNONF P , BELLOLI C et al. Prediction of relapse in patients with Crohn's disease in remission : a simplified index using laboratory tests, enhanced by clinical characteristics Eur J. Gastroenterol Hepato., 1994, 6 : 955-961.
LOUIS E , BELAICHE J., VAN KEMSEKE C. et al. Soluble interleukin-2 receptor in Crohn's disease. Assessment of disease activity and prediction of relapse. Dig. Disease Sciences, 1995, 40 : 1750-1756.
LOUIS E., BELAICHE J , VAN KEMSEKE C. et al Crohn's disease relapse by interleukin-6 serum level Eur. J. Gastro Hepato (in press).
SINGLETON J.W., SUMMERS R.W., KERN F. et al. A trial of sulfasalazine as an adjunctive therapy in Crohit's disease Gastroenterology, 1979, 77 , 8887-8897.
MODIGLIANI R., COLOMBEL J F., DUPAS J L et al Mesalamine in Crohn's disease with steroid-induced remission effect on steroid withdrawal and remission maintenance. Gastroenterology, 1996, 110 : 688-693
EWE K., PRESS A G., SINGE C.C. et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenteroloy, 1993, 105 367-372
LEREBOURS E., GALMICHE J.P. FOUIN-FORTUNET H. et al. Etude de l'utilité d'une corticothérapie au cours des poussées aigues de maladie de Crohn traitées par alimentation parentérale. Gastroenterol. Cllin. Biol , 1982, 6 : 1450-1455.
VAKIL N., SPARBERG M. Steroid-related osteonccrosis in inflarnmatory bowel disease. Gastroenterology, 1989, 96 : 62-67.
COMPSTON J.E., JUDD D., CRAWLEY E O. et al Osteoporosis in patients with inflammatory bowel disease Gut, 1987, 28 : 410-415.
PIGOT F., ROUX C., CHAUSSADE S. et al Low bone mineral density in patients with inflammatory bowel disease. Dig. Dis Sci., 1992, 37 1396-1403
ROUX C., ABITBOL V., CHAUSSADE S. et al. Bone loss in patients with inflammatory bowel disease . a prospective study. Osteoporosis Int , 1995, 5 . 156-160.
CROUCHER P.I., VEDI S., MOTLEY R.J. et al Reduced bone formation in patients with osteoporosis associated with inflammatory bowel disease. Osteoporosis Int., 1993, 3 : 236-241.
ABITBOL V., ROUX C., CHAUSSADE S. et al. Metabolic bone assesment in patients with inflammatory bowel disease Gastroenterology. 1995, 108 : 417-422.
GREENBERG G.R., FEAGAN B.G., MARTIN F. et al. Oral budesonide for active Crohn's disease. N Engl J Med. 1994, 331 : 836-841.
GROSS V., CAESAR I., ANDUS T. et al. Dose-finding study with oral budesonide in patients with active Crohn's ileocolitis. Gastroenterology, 1997, 112 (4 suppl.) : A 986 (abstr.).
CAMPIERI M., FERGUSON A., DOE W et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease Gut, 1997, 41 : 209-214.
RUTGEERTS P., LOFBERG R., MALCHOW H. et al. A comparison of budesonide with prednisolone for active Crohn's disease. N. Engl. J. Med., 1994, 331 : 842-845.
SACHAR D B Budesonide for inflammatory bowel disease. Is it a magic bullet ? N. Engl. J. Med., 1994, 331 : 873-874.
SINGLETON J.W., HANAUER S.B , GITNICK G.L. et al Mesalamine capsules for the treatment of active Crohn's disease : result of a 16-week trial Gastroenterology, 1993, 104 : 1293-1301.
THOMSEN O.O., CORTOT A., JEWELL D. et al. Budesonide CIR is more effective than mesalazine in active Crohn's disease. A 16 week, international randomized double-blind multicentrique trial. Gastroenterology, 1997, 112 (4 suppl) : A 1104 (abstr.)
LOFBER R. New steroids for inflammatory bowel disease Inflamm. Bowel Dis , 1995, 1 , 135-141.
WRJGHT J P., JARNUM S., SCHAFFALITZKY DE MUCKADEL O et al. Oral fluticasone propionate compared with prednisolone in treatment of active Crohn's disease : a randomized double-blind multicentre study. Eur J. Gastro Hepato., 1993, 5 : 499-503.
D'HAENS G.R., RUTGEERS P. How should corticosteroids be used in inflammatory bowel disease ? Clinical Immunotherapeutics, 1996, 5 : 334-340
ANDUS T., GROSS V., CAESAR T, et al. Replacement of conventional steroids by budesonide in active or inactive Crohn's disease. Interim analysis of an open, prospective, multicenter trial. Gastroenterology, 1995, 108 : A 771 (abstr.).
NOVACEK G , KLEINBERGER M., VOGELSANG H. et al Budesonide in glucocorticoid dependent chronic active Crohn's disease, a pilot study Z gastroenterol , 1995, 33 : 251-254.
PRANTERA C., ZANNONI F., SCRIBANO M.I. et al. An antibiotic regimen for the treatment of Crohn's disease - a randomized, controlled clinical trial of metronidazole plus ciprofloxacine Am. J. Gastroenterol., 1996, 91 : 328-332
FELINER J.B , ADLER D J., KORELITZ B.I. The safety of corticosteroid therapy in Crohn's disease with an abdominal mass. Am. J. Gastroenterol., 1991, 86 : 1450-1455